Cell cycle effects and induction of premitotic apoptosis by irofulven in synchronized cancer cells

Cancer Biology and Therapy

Volumn 3, Issue 11, 2004, Pages 1137-1142

  Woynarowski, Jan M ^a,c   Woynarowska, Barbara A ^a   Trevino, Alex V ^a   Salinas, Richard ^a   Herman, Terence S ^a   Waters, Stephen J ^b   MacDonald, John R ^b  

^a University of Texas Health Science Center   (United States)

^b GUILFORD PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Cell cycle effects; Irofulven; Premitotic apoptosis; Synchronized cells

Indexed keywords

6 HYDROXYMETHYLACYLFULVENE; CELL DNA; CELL PROTEIN; PROTEIN BCL 2; ALKYLATING AGENT; IROFULVEN; SESQUITERPENE;

APOPTOSIS; ARTICLE; CANCER; CANCER CELL; CELL CULTURE; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL SYNCHRONIZATION; DNA REPLICATION; DNA STRAND BREAKAGE; DRUG EFFECT; DRUG EXPOSURE; FEMALE; HELA CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKEMIA CELL; MITOSIS; TUMOR REGRESSION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM;

ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; DNA REPLICATION; G1 PHASE; GENE EXPRESSION REGULATION; HELA CELLS; HUMANS; MITOSIS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; S PHASE; SESQUITERPENES;

EID: 22144450723     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.11.1216     Document Type: Article

References (31)

1. Roninson IB, Broude EV, Chang BD. If not apoptosis, then what? Treatment-induced, senescence and mitotic catastrophe in tumor cells. Drug Resist Updat 2001; 4:303-13.
2. Van Cruchten S, Van Den Broeck W. Morphological and biochemical aspects of apoptosis, oncosis and necrosis. Anat Histol Embryol 2002; 31:214-23.
3. Rich T, Allen RL, Wyllie AH. Defying death after DNA damage. Nature 2000; 407:777-83.
4. Held KD. Radiation-induced apoptosis and its relationship to loss of clonogenic survival. Apoptosis 1997; 2:265-82.
5. Schober C, Gibbs JF, Yin MB, Slocum HK, Rustum YM. Cellular heterogeneity in DNA damage and growth inhibition induced by ICI D1094, thymidylate synthase inhibitor, using single cell assays. Biochem Pharmacol 1994; 48:997-1002.
6. Woynarowska BA, Woynarowski JM. Preferential Targeting of Apoptosis in Tumor Versus Normal Cells. Biochimica Biophysica Acta 2002; 1587:309-17.
7. Woynarowska BA, Roberts K, Woynarowski JM, MacDonald JR, Herman TS. Targeting apoptosis by hydroxymethylacylfulvene in combination with gamma radiation in prostate tumor cells. Radiat Res 2000; 154:429-38.
8. 2-phase checkpoint. Int J Radiat Biol 2002; 78:807-19.
9. Shinomiya N. New concepts in radiation-induced apoptosis: 'premitotic apoptosis' and 'postmitotic apoptosis'. J Cell Mol Med 2001; 5:240-53.
10. Shinomiya N, Kuno Y, Yamamoto F, Fukasawa M, Okumura A, Uefuji M, et al. Different mechanisms between premitotic apoptosis and postmitotic apoptosis in X-irradiated U937 cells. Int J Radiat Oncol Biol Phys 2000; 47:767-77.
11. Woynarowska BA, Woynarowski JM, Herzig MC, Roberts K, Higdon AL, MacDonald JR. Differential cytotoxicity and induction of apoptosis in tumor and normal cells by hydroxymethylacylfulvene (HMAF). Biochem Pharmacol 2000; 59:1217-26.
12. Woynarowski JM, Napier C, Koester SK, Chen SF, Troyer D, Chapman W et al. Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114). Biochem Pharmacol 1997; 54:1181-93.
13. Herzig MC, Liang H, Johnson AE, Woynarowska B, Woynarowski JM. Irofulven induces apoptosis in breast cancer cells regardless of caspase-3 status. Breast Cancer Res Treat 2002; 71:133-43.
14. Herzig MCS, Trevino AV, Liang H, Salinas R, Waters SJ, MacDonald JR, et al. Apoptosis induction by the dual-action DNA- and protein-reactive antitumor drug irofulven is largely Bcl-2-independent. Biochem Pharmacol 2003; 65: 503-13.
15. Wang W, Waters SJ, MacDonald JR, Von Hoff DD, Strodel WE, Miller AR. Irofulven (6-hydroxymethylacylfulvene, MGI 114) induces caspase 8 and 9-mediated apoptosis in human pancreatic adenocarcinoma cells. Anticancer Res 2001; 21:1789-94.
16. Van Laar ES, Roth S, Weitman S, MacDonald JR, Waters SJ. Activity of irofulven against human pancreatic carcinoma cell lines in vitro and in vivo. Anticancer Res 2004; 24:59-65.
17. Van Laar ES, Weitman S, MacDonald JR, Waters SJ. Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models. Prostate 2004; 59:22-32.
18. Poindessous V, Koeppel F, Raymond E, Comisso M, Waters SJ, Larsen AK. Marked activity of irofulven toward human carcinoma cells: comparison with cisplatin and ecteinascidin. Clin Cancer Res 2003; 9:2817-25.
19. Woynarowska BA, Woynarowski JM, Liang H, Herzig MCS, Leal BZ, Vallejo M, et al. Irofulven binding and inactivation of purified and cellular redox-controlling proteins. Proc Amer Assoc Cancer Res 2004; 45:Abstr 1510.
20. Herzig MCS, Arnett B, MacDonald JR, Woynarowski JM. Drug uptake and cellular targets of hydroxymethylacylfulvene (HMAF). Biochem Pharmacol 1999; 58:217-25.
21. Yin DX, Schimke RT. BCL-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells. Cancer Research 1995; 55:4922-8.
22. Yin DX, Zhu L, Schimke RT. Tetracycline-controlled gene expression system achieves high-level and quantitative control of gene expression. Anal Biochem 1996; 235:195-201.
23. Woynarowski JM, Beerman TA. Inhibition of DNA replication in HeLa S3 cells by macromomycin-I, an antitumor protein antibiotic. Mol Pharmacol 1980; 18:491-6.
24. 1 phase-dependent expression of bcl-2 mRNA and protein correlates with chemoresistance of human cancer cells. Mol Pharmacol 2000; 58:1001-10.
25. Yamaguchi H, Paranawithana SR, Lee MW, Huang Z, Bhalla KN, Wang HG. Epothilone B analogue (BMS-247550)-mediated cytotoxicity through induction of Bax conformational change in human breast cancer cells. Cancer Res 2002; 62:466-471.
26. Gorczyca W, Bruno S, Melamed MR, Darzynkiewicz Z. Cell cycle-related expression of p120 nucleolar antigen in normal human lymphocytes and in cells of HL-60 and MOLT-4 leukemic lines: effects of methotrexate, camptothecin, and teniposide. Cancer Res 1992; 52:3491-4.
27. Li X, Traganos F, Darzynkiewicz Z. Simultaneous analysis of DNA replication and apoptosis during treatment of HL-60 cells with camptothecin and hyperthermia and mitogen stimulation of human lymphocytes. Cancer Res 1994; 54:4289-93.
28. Del Bino G, Bruno S, Yi PN, Darzynkiewicz Z. Apoptotic cell death triggered by camptothecin or teniposide. The cell cycle specificity and effects of ionizing radiation. Cell Prolif 1992; 25:537-48.
29. Huang X, Traganos F, Darzynkiewicz Z. DNA damage induced by DNA topoisomerase I-and topoisomerase II-inhibitors detected by histone H2AX phosphorylation in relation to the cell cycle phase and apoptosis. Cell Cycle 2003; 2:614-9.
30. Liang H, Leal BZ, Baluna R, Keovongxay P, R.A. S, Woynarowska BA. Growth inhibition and apoptosis by irofulven in combination with g-radiation in model brain tumor cells. Proc Am Assoc Cancer Res 2002; 43:130.
31. Yoshida M, Hosoi Y, Miyachi H, Ishii N, Matsumoto Y, Enomoto A, et al. Roles of DNA-dependent protein kinase and ATM in cell-cycle-dependent radiation sensitivity in human cells. Int J Radiat Biol 2002; 78:503-12.